Mysim Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.40 M
- Paid Up Capital ₹ 1.00 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 957.04%
- Ebitda 2114.47%
- Net Worth 139.52%
- Total Assets 1338.49%
About Mysim Therapeutics
Mysim Therapeutics Private Limited (MTPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 November 2020 (Four years and three months 1 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.40 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Mumtaz Siddique and Irshad Gojri serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299DL2020PTC373484
- Company No.
373484
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Nov 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mysim Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mumtaz Siddique  | Director | 20-Nov-2020 | Current |
| Irshad Gojri | Director | 22-Mar-2024 | Current |
Financial Performance of Mysim Therapeutics.
Mysim Therapeutics Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 957.04% increase in profit. The company's net worth Soared by an impressive increase of 139.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mysim Therapeutics?
In 2021, Mysim Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mysim Healthcare Private LimitedMumtaz Siddique and Irshad Gojri are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mysim Therapeutics?
Mysim Therapeutics has a workforce of 31 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mysim Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mysim Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
